Story
Lion's Mane · Hericium erinaceus
Last updated
In one pass Lion's mane (known in China as the monkey-head mushroom, houtou gu) is an edible mushroom that in recent years has been sold as a brain mushroom that improves memory and even reverses Alzheimer's disease. Not this — Lion's Mane regrows neurons — Raised nerve growth factor has been seen only in cells and rodents; the human evidence on thinking and memory is small, short-term randomized trials.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
What it is and why it got popular
Lion's mane (known in China as the monkey-head mushroom, houtou gu) is an edible mushroom that in recent years has been sold as a brain mushroom that improves memory and even reverses Alzheimer's disease. First, the plain fact: the human evidence for these claims is thin, and most of it is marketing.
What makes it tempting is two classes of small molecules: hericenones in the mushroom itself (the fruiting body), and erinacines in its root system (the mycelium). In cell experiments, compounds like these make nerve cells produce more of their own nerve growth factor (NGF), a protein that keeps neurons alive and helps nerves grow new branches; some cell and animal studies have also reported a rise in brain-derived neurotrophic factor (BDNF). The direction sounds right. The trouble is that several hurdles still stand between the culture dish and a human being.
One more distinction will come up again and again: what you buy at the grocery store is the mushroom itself, while many supplements sell mycelium grown on grain, which may carry a lot of grain starch mixed in.
What makes it tempting is two classes of small molecules: hericenones in the mushroom itself (the fruiting body), and erinacines in its root system (the mycelium). In cell experiments, compounds like these make nerve cells produce more of their own nerve growth factor (NGF), a protein that keeps neurons alive and helps nerves grow new branches; some cell and animal studies have also reported a rise in brain-derived neurotrophic factor (BDNF). The direction sounds right. The trouble is that several hurdles still stand between the culture dish and a human being.
One more distinction will come up again and again: what you buy at the grocery store is the mushroom itself, while many supplements sell mycelium grown on grain, which may carry a lot of grain starch mixed in.
Background · How it got famous, and why anecdotes fail
Lion's mane looks like a clump of white coral, or a lion's mane: strands of white, needle-like spines hanging from dead wood. It is an edible mushroom in its own right, and steamed or sautéed it tastes a little like crab. Traditional Chinese medicine uses it to settle the stomach and calm the mind, and in Japan it is called Yamabushitake.Its sudden fame in recent years came mainly from short videos, podcasts and a mushroom documentary, plus a few personal stories about "reversing dementia" — every one of them a single, uncontrolled case. The hype is running far ahead of the evidence.
Why personal stories are especially unreliable on this topic
Not because the people telling them are dishonest, but because cognitive function as an outcome has three properties that strip a single case of its power to judge:
It fluctuates every day. The same person's memory and focus can swing a good deal with a good or bad night's sleep, a cold, or that day's mood. People almost always decide to do something at a low point, and after a low point things usually recover on their own. That is regression to the mean, and it has nothing to do with whatever you started taking that dayIt has no objective scale. Blood pressure has a number; how clear your head feels does not. And a person's rating of their own cognition is exactly the kind of feeling most easily moved by expectation: you spent the money, you hope it works, you remember to take it every day, and those three things alone will lift a self-ratingChange rarely happens alone. Someone who decides to take their brain seriously usually starts sleeping earlier, exercising and drinking less at the same time. All of those have been studied for cognition far more thoroughly than the mushroom, but the credit often goes to whatever was added last
So from here on the approach is this: ignore the stories and look only at trials that have a control group, use an objective scale and state in advance what they will measure. You will then find that such trials are very few, and every one of them is small.
Chapter 2
How it might act on nerves
If lion's mane really protects the brain, the most likely route is by making nerve cells produce more of two neurotrophic factors — proteins that help neurons survive and grow new connections. NGF (nerve growth factor) looks after neuron survival, the adaptability of synapses and the myelin sheath, and this signaling weakens with age; in Alzheimer's disease, its signaling pathway has been found to be damaged. BDNF (brain-derived neurotrophic factor) does similar work and is especially active in the hippocampus and prefrontal cortex: it rises when you exercise, sleep enough and learn new things, and falls under long-term stress and depression. Lion's mane's theoretical selling point is adding fuel to this system from outside.
Adding fuel sounds like flipping a switch, but it is really a building project measured in weeks: growing axons, building synapses, reinforcing connections, and every step needs the cell to transcribe genes, make proteins and haul materials to the site. So feeling sharper on the day you take it almost cannot come from this route.
The weakest link of this chain in people is that nobody has measured how much of these molecules actually reaches the human brain.
Adding fuel sounds like flipping a switch, but it is really a building project measured in weeks: growing axons, building synapses, reinforcing connections, and every step needs the cell to transcribe genes, make proteins and haul materials to the site. So feeling sharper on the day you take it almost cannot come from this route.
The weakest link of this chain in people is that nobody has measured how much of these molecules actually reaches the human brain.
Mechanism · What a neuron builds once NGF rises
NGF went up explains nothing by itself. To understand it, you have to follow the signal through the chain below.Step 1 · NGF has to be caught first. NGF does not enter the cell. It docks on a receptor on the neuron's surface called TrkA. Two receptors are pulled together by the same batch of NGF and activate each other, and the signal starts at the cell membrane. A neuron with too few receptors, or broken ones, will not respond no matter how high you pile the NGF. That is the first ceiling, and it is where the intuition a bit more in, a bit more growth goes wrong.
Step 2 · The signal is sent back to the nucleus. The caught signal does not act on the spot. It is packed into a small vesicle and hauled backward (retrograde) along tracks inside the axon, all the way to the cell body. When the nucleus receives it, gene expression changes and the cell starts making building materials: parts of the cell skeleton, membrane, proteins the synapse will need. Notice the timescale of this step: transport, transcription and translation take hours to days.
Step 3 · The growth cone pushes outward. The tip of an axon carries a palm-like structure called the growth cone. It puts out many fine filaments to probe its surroundings, and when it finds a good direction, it lays down a stretch of cell skeleton that way, so the whole axon grows a little longer. NGF does two jobs here at once: it grants the building permit (so the cell has materials to use) and it gives direction (grow toward whichever side has more of it).
Step 4 · Meet a target, build a synapse. When the growth cone meets a suitable target cell, it stops. Both sides set the right proteins out on the contact surface, and a new synapse slowly takes shape. Only at this step do the two neurons actually gain a new line between them — and lines are the physical form of memories and skills.
Step 5 · Use it or lose it. A new connection is not permanent once built. It has to be activated again and again to be reinforced, or it gets pruned. The nervous system is stingy about this: keeping a synapse costs energy all the time, so unused ones are taken apart.
String these five steps together and three inferences follow:
This is construction, not stimulation. Things like caffeine change a neuron's firing on the spot and work within minutes. The five steps above need transcription, transport and building, and their timescale is weeks. So feeling sharper on the day you take it almost cannot come from this route; at that point the project has not even broken groundWhy the effect fades after you stop. In Mori 2009, a trial in people with mild cognitive impairment (MCI — memory and thinking worse than their peers', but not dementia), scores dropped clearly 4 weeks after participants stopped taking it. Seen through step 5, this makes sense: the outside push is withdrawn, the newly built connections are no longer favored for upkeep, and they fall back under the normal pruning rules. If this mechanism holds, that is how it should look; but a falling score does not, by itself, prove the mechanism. At the least, it shows this is not a one-time repairWhy the signal may be clearer in people who already have a problem. One possible explanation: in healthy young people this pathway is already running normally, and the bottleneck is not the amount of NGF, whereas a declining system may be short of exactly this link. A shortfall-filling intervention showing no effect in people without the shortfall is not a contradiction. It may be one reason the signal is weakest in healthy people in the human trials discussed later
Evidence · Cell and animal data, and four gaps
In a cell experiment by a Malaysian team (Lai 2013), a water extract of lion's mane made a commonly used nerve cell line secrete more of its own NGF, and the cells grew more vigorous branches, with a stronger effect when combined with added NGF; but in the same experiment it failed to protect the cells against oxidative stress. Promoting growth is not the same as saving the cell. Animal experiments have produced attractive reports too: mice and rats fed the extract showed higher BDNF in the hippocampus and better maze memory; in transgenic mice that model Alzheimer's disease (APP/PS1), beta-amyloid plaques decreased and cognition improved; and after a peripheral nerve injury, regrowth was faster. All of these animal results can only be read as a direction.The problem is that several gaps sit between the dish, the mouse and a person:
Can it get into the brain? Hericenones and erinacines are small molecules, and animal data suggest they can cross the blood-brain barrier. Large molecules such as the polysaccharides cannot get in, and can only act indirectly through the immune system and the signaling between gut and brain. And crossing is not the same as working: the concentration still has to build up in the right cells at the right timeDo the doses line up? The amounts fed to animals are not small for their body weight, and whether the roughly 1–3 g a day used in human trials is enough once scaled to people has never been specifically tested. When you buy a product, do the arithmetic: can you reach the gram-level daily dose used in the trials?Is the duration long enough? Animal models run for weeks to months, already a large slice of a mouse's life; Alzheimer's disease in people unfolds over many years, while the human trials here run from as short as 4 weeks to at most 49 weeks, so long-term effects are simply invisibleIs it even the same thing? Animal studies often use purified hericenones and erinacines, while human trials use dried fruiting-body powder, standardized extracts or grain-and-mycelium mixtures, and the content of active compounds can differ widely
So the honest position is this: there is a signal along this mechanistic line, and cell and animal data both suggest the pathway is real; but translation to people is at an early stage, most human trials are small, and the certainty of the evidence is low. It is not a completely useless placebo, and it is nowhere near a miracle drug that reverses Alzheimer's disease. A more accurate label: an early candidate whose mechanism makes sense but which has not yet been properly tested in the clinic.
Mechanism · NGF itself cannot cross into the brain
The five-step building chain above only runs once NGF is already near the neuron. Now ask a question further upstream: where does that NGF come from?Here is a fact almost every piece of marketing skips: NGF is a large protein, and it cannot cross the blood-brain barrier.
The blood-brain barrier is the ring of welded-shut seams between the cells lining the brain's blood vessels. Elsewhere in the body, capillary walls leave gaps between cells, and molecules can squeeze through; in the brain, tight junctions seal those gaps. Only small, fat-soluble molecules can pass straight through cell membranes, and large molecules either use a dedicated transporter or do not get in at all. There is no door open for a protein the size of NGF.
So the route of supplementing NGF directly was blocked from the start: none of the NGF you swallow reaches the brain, and in any case the digestive tract breaks proteins into fragments first.
The route lion's mane claims is therefore not delivering NGF into the brain but getting the brain to make more of its own. The full version goes like this:
The hericenones and erinacines in lion's mane are small molecules, not proteinsSmall molecules may be able to cross the blood-brain barrier, and animal pharmacokinetic data support thisOnce in brain tissue, they act on cells in the brain and make those cells synthesize and release more NGF themselvesThe extra NGF made inside the brain then runs through the five building steps
Each link in this chain has its own evidence, but the strength differs sharply. The thinnest is the middle link: there are no direct human data on what concentration these small molecules reach in human brain tissue. What can be measured in people is only the amount that briefly appears in blood plasma after swallowing a dose; the jump from plasma to brain tissue is currently extrapolated from animal models.
Why this link matters so much, rather than being just one more thing not yet measured. Because it is the hub of the whole story. Those elegant lab experiments all work by adding the molecule straight onto cultured nerve cells, which assumes the molecule has already arrived. If the amount that actually reaches brain tissue is far below the concentration in the dish, then none of the cell data is false — it just cannot reach. That is not a fraud problem; it is a dose-arrival problem, the same thing the dose gap among the four gaps is saying.
Spelling this out is not the same as saying it does not work. The honest statement is: this is a chain in which every link makes sense, but not one link has been measured directly in a human brain. That is stronger than a supplement that cannot even tell a mechanism story, and much weaker than an intervention already verified in people.
Once you know where the break is, you know what kind of new research would actually move the conclusion: not another small questionnaire trial, but someone actually measuring how much reaches the human brain. The next time you see a new lion's mane study, check first whether it measured this link.
Chapter 3
Few, small human trials
Take the marketing filter off and the trials actually done in people are few, and every one of them is small.
The most-cited is Mori 2009: 30 Japanese adults aged 50–80 with mild cognitive impairment (MCI — memory and thinking worse than their peers', but not dementia) were randomized into two groups of 15. One group took 3 g a day of lion's mane powder tablets (4 tablets of 250 mg each, three times a day), and the other took a placebo, for 16 weeks. At weeks 8, 12 and 16, the lion's mane group scored clearly higher than the placebo group on a cognitive scale (the revised Hasegawa Dementia Scale, HDS-R); 4 weeks after stopping, the scores dropped clearly again, suggesting it only works while you keep taking it.
This is a positive signal, but remember its limits along with it: only 30 people in total; mild cognitive impairment is not Alzheimer's disease; the treatment period was short; and more than a decade later, no larger independent trial has reproduced it.
The most-cited is Mori 2009: 30 Japanese adults aged 50–80 with mild cognitive impairment (MCI — memory and thinking worse than their peers', but not dementia) were randomized into two groups of 15. One group took 3 g a day of lion's mane powder tablets (4 tablets of 250 mg each, three times a day), and the other took a placebo, for 16 weeks. At weeks 8, 12 and 16, the lion's mane group scored clearly higher than the placebo group on a cognitive scale (the revised Hasegawa Dementia Scale, HDS-R); 4 weeks after stopping, the scores dropped clearly again, suggesting it only works while you keep taking it.
This is a positive signal, but remember its limits along with it: only 30 people in total; mild cognitive impairment is not Alzheimer's disease; the treatment period was short; and more than a decade later, no larger independent trial has reproduced it.
Evidence · The early-Alzheimer pilot and what pilots do
The other paper often held up as evidence of reversing Alzheimer's disease is Li 2020 (Taiwan). Forty-nine people with mild Alzheimer's disease were randomized: one group took 3 capsules a day of mycelium enriched with erinacine A (350 mg per capsule), and the other took identical-looking placebo capsules, for 49 weeks; 41 people completed the study. After 49 weeks, the placebo group's score on the Cognitive Abilities Screening Instrument (CASI) had fallen significantly, the mycelium group's Mini-Mental State Examination (MMSE) score had risen significantly, and the two groups differed significantly on instrumental activities of daily living (IADL — abilities such as shopping, handling money and using the phone). The direction of the data does look good, but it is only a small exploratory pilot: one ethnic group, never replicated, and several authors were employed by the company that makes this mycelium, which also supplied the study materials. All of that belongs on the ledger.Why company involvement has to be stated openly
A funder is not the same as fraud. But it can shape how a result looks through entirely legitimate routes: which outcome the design picks, how often it is measured, and whether a negative result gets published. So the industry custom is to disclose, and the right response for a reader is not so I don't believe it but so it needs an independent team to replicate it. From the end of this pilot to now, that replication has not appeared.
A more basic question: what is a pilot study for?
The usual purpose of a pilot is not to prove that something works but to answer can this trial be run: is the dose tolerable, can participants be recruited, can the outcome be measured, how many drop out? Its sample size is calculated for those questions, not to detect a treatment effect.
That has a statistical consequence worth remembering: when the sample is small, a real effect and random noise look exactly alike. So a positive result from a small pilot may be real, or it may be how this particular batch of people happened to turn out, and from this one study alone you cannot tell which.
The only claim it is entitled to support is this one: a larger trial is worth running.
Generalize that and you get a very practical filter: when a supplement is said to be backed by clinical trials, ask three things first — how many people? Was there a placebo control? Has another team gotten the same result? The third question matters most, and it is the one this mushroom currently cannot answer.
Evidence · Small trials on mood and healthy memory
Vigna 2019: mood in people with overweight or obesity (Evid Based Complement Alternat Med)77 Italian volunteers with overweight or obesity who also had mood, sleep or binge-eating problems, all on a low-calorie diet, were randomized into two groups: 40 added lion's mane and 37 followed the diet aloneThe lion's mane group took 3 capsules a day of 500 mg each, made up of 80% mycelium and 20% fruiting-body extract, for 8 weeksResults: scores for depression, anxiety and sleep problems fell; blood pro-BDNF (the precursor of BDNF) rose, while BDNF itself did not change noticeablyLimits: the control group did not take a placebo, and the authors themselves call it a preliminary study that needs placebo-controlled trials to confirm it; participants had a combined condition (obesity plus mood problems); and the treatment period was short
Nagano 2010: mood in healthy women (Biomed Res)
30 women were randomized (26 analyzed), with an average age of about 40; the paper classes them as healthy, not as a menopausal groupThey ate 4 cookies a day, each containing 0.5 g of fruiting-body powder, for 2 g in total, over 4 weeksResults: within the lion's mane group, before-and-after scores fell on a depression scale (CES-D) and an index of vague physical complaints (ICI); but only two items of the ICI beat placeboLimits: small sample, short treatment, and most of the improvement is a before-and-after comparison within one group, not a comparison with placebo
Saitsu 2019: cognition in healthy people over 50 (Biomed Res)
The analysis covered 31 healthy people over 50, who took 4 tablets a day, each containing 0.8 g of fruiting-body powder, for 3.2 g a day, over 12 weeksResults: of three tests, only the Mini-Mental State Examination (MMSE) reached significance; the Benton visual retention test and a standard verbal paired-associate learning test (S-PA) did notLimits: the effect in healthy people was weak, and the test that reached significance was the bluntest one — the MMSE is a dementia screening scale, not a dedicated memory test
Directions with only cell, animal or case evidence
Uses such as peripheral nerve injury, multiple sclerosis, stomach ulcers and fighting tumors currently rest only on cell experiments, animal experiments or scattered case reports. There are no decent human trials, and the certainty of the evidence is very low.
Evidence · Popular claims and where they really stand
Popular claims with no human trials behind themPrevents Alzheimer's disease: no large, long-term randomized trialsReverses Alzheimer's disease: Li 2020 is a pilot and does not amount to evidence of reversal; personal stories do not countSharper focus, faster learning: becoming sharper on the day a healthy person takes it has never been tested in a randomized trialThe Stamets Stack expands consciousness: no randomized trials at all
Is there a pooled analysis?
The trials here are too few and too small, and they used different products (fruiting-body powder, mycelium, mixtures of the two) and different measuring tools, so no credible pooled result can be produced yet. That they cannot be pooled is itself a sign that the certainty of the evidence is low.
How it compares with other ways to protect the brain
Lion's mane: low certainty of evidence — a few small trials that disagree with each other and have not been replicatedWorking on diet, exercise, cognitive training and vascular risk factors together: the Finnish FINGER randomized trial ran for 2 years in older adults at higher risk of cognitive decline, and overall cognitive performance was better than in the control group. That is the effect of several measures together, and it cannot say which one deserves the creditEnough sleep (7–9 hours a night) and regular exercise: the evidence comes mainly from observational studies plus some randomized trials, and it is far more thorough than for lion's mane
Wait for more evidence, or try it now?
For waiting: put your money and time first into things that have been studied more thoroughly — exercise, sleep, dietFor trying: no serious side effects have shown up in the trials so far, you can simply stop, and some people feel subjectively betterMiddle ground: if you want to try it, use a product labeled as fruiting body with a third-party test report, take roughly the 1–3 g a day used in the trials for 8–12 weeks, compare objective tests before and after, and do not expect it to reverse Alzheimer's disease
ngandu-2015-finger
Chapter 4
Some products are mostly grain
The biggest trap in the lion's mane market is that what you pay for may not be mostly lion's mane.
The key is the difference between the mushroom itself (the fruiting body) and the mycelium. The fruiting body is the actual mushroom that grows up and is picked and dried; the mycelium is its root system, which commercial growers usually raise on grain such as rice or wheat bran. Some makers do not separate the mycelium from the grain, but dry and grind the whole bed and sell it, so much of the weight is really grain starch. Such a powder naturally carries less of the β-glucan in the mushroom's cell walls (the most-studied kind of mushroom polysaccharide), and not necessarily much of the erinacines that animal studies focus on either.
The human trials cited here used dried lion's mane powder (Mori 2009), fruiting-body powder (Saitsu 2019, Nagano 2010), and mycelium enriched with erinacine A that was grown by fermentation in a liquid medium (Li 2020) — none of them a powder ground together with its grain bed. Before you buy, find out which kind is in the bottle in your hand.
The key is the difference between the mushroom itself (the fruiting body) and the mycelium. The fruiting body is the actual mushroom that grows up and is picked and dried; the mycelium is its root system, which commercial growers usually raise on grain such as rice or wheat bran. Some makers do not separate the mycelium from the grain, but dry and grind the whole bed and sell it, so much of the weight is really grain starch. Such a powder naturally carries less of the β-glucan in the mushroom's cell walls (the most-studied kind of mushroom polysaccharide), and not necessarily much of the erinacines that animal studies focus on either.
The human trials cited here used dried lion's mane powder (Mori 2009), fruiting-body powder (Saitsu 2019, Nagano 2010), and mycelium enriched with erinacine A that was grown by fermentation in a liquid medium (Li 2020) — none of them a powder ground together with its grain bed. Before you buy, find out which kind is in the bottle in your hand.
In practice · How one ratio shows if grain was added
Grain dilution is not a one-off: in the United States, third-party testing organizations and industry insiders have run market surveys reporting that a good share of products labeled as mushroom are mainly grain-and-mycelium powder. We could not verify the raw data of those surveys, so their percentages are not given here. Fortunately, this kind of dilution can be detected.Why one ratio can tell real from fake
The logic of this test is clean and worth spelling out on its own: it is a general way to see through an ingredient label, and it works for other product types too.
The main structural material of a mushroom's cell wall is β-glucan; the main energy store in grain (rice, wheat bran) is starch, which is chemically an α-glucan and releases maltose and glucose when broken down. Each raw material carries a marker the other lacks. So:
High β-glucan and little starch: it is mostly mushroomThe reverse, lots of starch and little β-glucan: it is mostly grain
The key is to look at the ratio, not the absolute amount. Absolute amounts can be diluted, concentrated or muddled with unit conversions, but the ratio of the two components reflects the identity of the raw material, and whatever is mixed in cannot hide: add grain, and starch goes up while β-glucan goes down, so the ratio gives it away at once.
"Polysaccharides" on a label may include starch, and that applies even to products used in trials. In Vigna 2019, the polysaccharide content stated for the product was measured as total glucan, α plus β together.
That is also why a milligram figure on the label carries almost no information. Milligrams describe the weight of the powder, and what the powder actually is is exactly the question being tested here. A spoonful of grain powder and a spoonful of fruiting-body extract weigh the same on a scale.
So what you are looking for is not a dose figure but proof of identity: it clearly says fruiting body, it gives a standardized β-glucan value, and it comes with a third-party test report. Once those three are in place, the milligram figure starts to mean something; before that, it only tells you how heavy the bag is.
Myth · Dual extraction, polysaccharides, erinacine A
Trap 2: dual extraction oversoldThe claim: dual extraction with water and ethanol pulls out every active compoundThe reality: water mainly extracts large polysaccharides such as β-glucan; ethanol extracts small molecules (hericenones, erinacines, triterpenes). Dual extraction sounds as if you get both classes, but how much each solvent pulls out, and how it is standardized, is hard to controlIt is not a scam, but perfectly preserves every active compound is marketing exaggeration
Trap 3: treating β-glucan and polysaccharides as the same thing
β-glucan: the polysaccharide in mushroom cell walls, the component studied for effects on the immune systemPolysaccharides: a much broader category that includes grain starch, and starch has no such pharmacological effectA label stating how much polysaccharide a product contains may be counting a large share of starch, leaving the real amount of mushroom β-glucan unknownWhat to look for is a standardized β-glucan value, not polysaccharides
Trap 4: suspicious erinacine A claims
Erinacines are found mainly in the mycelium, with only low levels in the fruiting bodyA product sold as pure fruiting body that nonetheless claims a high erinacine A content deserves a question about how it was measuredA genuine mycelium product standardized for erinacine A can be legitimate; Li 2020 used mycelium enriched with erinacine A
A checklist for choosing a product
The label clearly says fruiting bodyThere is a third-party test report giving the β-glucan content, with low starchThere is independent third-party certification (such as USP or NSF)The cultivation method, origin and growing medium are stated
Processed products such as lion's mane coffee and lion's mane chocolate: how much lion's mane each serving contains is usually hidden inside a blend, and reaching the gram-level daily dose used in the trials through them is not realistic.
Safety · Side effects, interactions, who should avoid
Safety: no serious problems seen in the trials so farIn the 16-week Mori 2009 trial, laboratory tests found no adverse effects from lion's maneIn the 49-week Li 2020 trial, 4 people (3 in the lion's mane group and 1 in the placebo group) dropped out because of abdominal discomfort, nausea or skin rash, and no other adverse events were reportedThe human trials have shown no sign of liver or kidney damage, but they are all small and cannot reveal rare side effectsDrug interactions have never been studied systematically: that means not studied, not studied and none foundPeople allergic to mushrooms: avoid it, since cross-reactions are possiblePregnancy and breastfeeding: no data, so to be cautious, do not use it
Theoretical concerns
Autoimmune disease: mushroom polysaccharides can activate the immune system in experiments, which in theory could make such a disease worse; the data are mixedClotting: some laboratory studies suggest its compounds may affect platelets; there are no human data. If you take an anticoagulant (warfarin, or one of the newer direct oral anticoagulants, ) or are facing surgery, tell your doctor first; with supplements of this kind, the usual cautious practice is to stop 2 weeks before surgeryLong-term use: the longest trial is Li 2020 at 49 weeks, and there are no data beyond that
Lion's mane coffee, chocolate and combinations like the Stamets Stack
Most are marketing packages, and the lion's mane in each serving falls far short of the gram-level doses used in trialsBrain-boosting on the side of a cup of coffee is a psychological comfort with no pharmacological meaningIf you really want to try it, buy a pure extract labeled as fruiting body, not coffee with lion's mane in it
Chapter 5
Who might try it, and how to tell
Whether lion's mane is worth trying depends on who you are and what you have already done. On the current evidence (low certainty: a few small trials whose results have not been replicated), the following two situations are reasonable.
You are 50–80, with mild cognitive impairment (memory and thinking worse than your peers', but not dementia) or a subjective sense that your mind has dulled, and you already have the basics in place: at least 7 hours of sleep, exercise, a Mediterranean-style diet, social contact, a hearing check. In that case you could try it for 8–12 weeks, but ground it in an objective test, such as the Montreal Cognitive Assessment (MoCA) or a simple memory score: test once before you start and again at 12 weeks; consider continuing only if there is a clear improvement, and stop if nothing changes. People naturally do a little better the second time they take the same test, so it is best to have a doctor give and judge the same scaleAs an add-on for mild to moderate anxiety or depression, provided you are already receiving proper treatment. Its human data on mood come from only two small trials, one of which had no placebo control. It can only be an add-on; it does not replace antidepressants or psychotherapy
You are 50–80, with mild cognitive impairment (memory and thinking worse than your peers', but not dementia) or a subjective sense that your mind has dulled, and you already have the basics in place: at least 7 hours of sleep, exercise, a Mediterranean-style diet, social contact, a hearing check. In that case you could try it for 8–12 weeks, but ground it in an objective test, such as the Montreal Cognitive Assessment (MoCA) or a simple memory score: test once before you start and again at 12 weeks; consider continuing only if there is a clear improvement, and stop if nothing changes. People naturally do a little better the second time they take the same test, so it is best to have a doctor give and judge the same scaleAs an add-on for mild to moderate anxiety or depression, provided you are already receiving proper treatment. Its human data on mood come from only two small trials, one of which had no placebo control. It can only be an add-on; it does not replace antidepressants or psychotherapy
Clinical · Early Alzheimer's and nerve injury
Early Alzheimer's disease, the condition studied in Li 2020. This must be done under the guidance of a neurologist. It must never replace standard medicines such as donepezil and memantine; at most it is an add-onRecovery from nerve injury, such as a peripheral nerve injury or nerve damage after chemotherapy. This is extrapolated from animal experiments, and no human trial supports it yetRecovery in this last item is not the same as a brain boost, and the two are worth separating
Peripheral nerves and neurons inside the brain are in very different situations. After a peripheral nerve is cut or injured, a natural regeneration program is already in place: the part beyond the cut is cleared away, the cells that form the myelin sheath line up into a channel, and the axon grows out again from the stump, back along that channel, all the way to its original target. The road is open; it is just slow: axons grow on the order of millimeters a day, so a long stretch of nerve takes months.
NGF's role in this process is exactly the one described in the mechanism chapter: supplying the growth cone with building materials and a direction signal. So in the peripheral-nerve setting, the neurotrophic-factor hypothesis fits most naturally: it pushes a program that is already running, like sending extra material to a machine that has already started.
Inside the brain, the situation is the opposite. Mature neurons in the central nervous system regenerate far more weakly, and the environment around them carries signals that inhibit axon growth. That is not a design flaw but a stability the adult brain maintains to keep what it has already learned. The same raise NGF intervention meets completely different resistance in these two places.
Once this layer is clear, you can see why this item, even though it does not yet have a single human trial, stands on firmer mechanistic ground than brain-boosting in healthy people — and why it deserves its own line instead of being folded into one sentence with brain-boosting.
Note: a smoother mechanism does not mean it works. The evidence for this item is still only an extrapolation from animal experiments. If you actually want to use it clinically (especially for nerve damage after chemotherapy), talk to your treating doctor first: chemotherapy regimens are already complicated, and adding something on your own is not a small matter.
In practice · When it is not worth trying
Situations where it is not worth it or not recommended① Healthy young adults who want to optimize their brains
In healthy people, the signal from randomized trials is weakThe same budget spent on exercise, sleep, reading, learning a language or learning an instrument pays back far more
② Taking it every day as lifelong prevention of Alzheimer's disease
There are no large, long-term randomized trialsIt is likely to be a lifelong wasteDo the better-studied things first: exercise, a Mediterranean-style diet, social contact, sleep, hearing care, and keeping blood pressure and blood glucose under control
③ Moderate to severe, late-stage Alzheimer's disease
Nerve degeneration is already severe, leaving little room for the NGF pathway to repair anythingThe right tools are medicines such as cholinesterase inhibitors and memantine, plus comprehensive careUsing lion's mane is misplaced hope
④ The Stamets Stack (lion's mane plus a microdose of psilocybin, a hallucinogen, plus niacin)
Not a single randomized trial has tested itPsilocybin is a prohibited drug in most countriesFollowing an influencer is not medicine
⑤ Mushroom allergy, pregnancy, breastfeeding
Avoid it
If you choose to try it: product and use
The label must say fruiting bodyThe β-glucan content is statedA third-party test report is publicly availableDose as in the trials: 1–3 g a day of fruiting-body powder, or an equivalent amount of extractTake it for 1–3 months and watch for change, and stop if nothing happens
In practice · How to tell if it is working for you
"It really makes me feel sharper" can come from three sources:A real effect: neurotrophic signaling and anti-inflammatory actionPlacebo: trust, expectation, and the feeling that I am doing something: when you started lion's mane, you also slept better, cut your stress and started exercising, and those are what is really working
How to tell them apart: use an objective cognitive test as your baseline and follow-up measure, not your feelings; then run a stopping test: stop for 4 weeks and see whether you return to baseline (in Mori 2009, scores dropped clearly 4 weeks after stopping).
Where to spend your money and time (ranked by how thoroughly each has been studied)
Regular exercise (around 150 minutes a week at moderate intensity): free, and studied for cognition more than any supplementEnough sleep (7–9 hours a night): freeA Mediterranean-style diet, social contact and learning: also studied far more thoroughly than supplementsLion's mane: low certainty of evidence, and it costs money every day
Where that leaves it
Lion's mane is an early candidate with a mechanism that makes sense, low-certainty human evidence and, so far, a good safety record. It is not something that reverses Alzheimer's disease, and it will not send your IQ soaring. What you hear in short videos and podcasts usually runs far ahead of the real evidence.
It can be an add-on option, but it should not be the main road. If you are genuinely worried about your cognitive health, exercise, sleep, a Mediterranean-style diet, social contact, hearing checks and control of blood pressure and blood glucose, taken together, are more dependable than any supplement.
The biggest problem with natural brain-booster marketing is that it gets people to skip the well-studied things and buy the thinly evidenced one. That is a classic misplacement of opportunity cost.
References · 6
- Lai, P.-L., Naidu, M., Sabaratnam, V., Wong, K.-H., David, R. P., Kuppusamy, U. R., et al. (2013). Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus from Malaysia. International Journal of Medicinal Mushrooms, 15(6), 539-554. Cell culture only (NG108-15 neuroblastoma-glioma cells; MRC-5 fibroblasts for toxicity): an aqueous H. erinaceus extract was not cytotoxic, induced NGF secretion and neurite outgrowth, and together with 10 ng/mL NGF gave the largest outgrowth (+60.6%); it failed to protect the cells against oxidative stress, so the authors call it neurotrophic but not neuroprotective. It measures no BDNF, no blood-brain-barrier passage and no animals, which this record once claimed (abstract, PMID 24266378). 10.1615/IntJMedMushr.v15.i6.30
- Mori, K., Inatomi, S., Ouchi, K., Azumi, Y., & Tuchida, T. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3), 367-372. 10.1002/ptr.2634
- Li, I.-C., Chang, H.-H., Lin, C.-H., Chen, W.-P., Lu, T.-H., Lee, L.-Y., et al. (2020). Prevention of early Alzheimer's disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Frontiers in Aging Neuroscience, 12, 155. N=49 mild AD adults × 49 wk → MMSE/CASI/IADL improved vs placebo. Full text: 41 completed and were analysed (20 EAHE, 21 placebo). Abstract: three 350 mg capsules/day of erinacine A-enriched mycelia (5 mg/g) vs placebo for 49 weeks; CASI fell significantly within the placebo group, MMSE improved within the EAHE group, and IADL differed between groups, so not all three were between-group differences. The mycelia were grown in submerged liquid culture. Grape King Bio paid the salaries of five authors and supplied the research material (full text and COI, PMC7283924; abstract, PMID 32581767). 10.3389/fnagi.2020.00155
- Vigna, L., Morelli, F., Agnelli, G. M., Napolitano, F., Ratto, D., Occhinegro, A., et al. (2019). Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity: could circulating pro-BDNF and BDNF be potential biomarkers? Evidence-Based Complementary and Alternative Medicine, 2019, 7861297. 77 overweight or obese adults with a mood or sleep disorder or binge eating, all on a low-calorie diet, were randomly allocated to the diet alone (n = 37) or the diet plus Micotherapy Hericium, 3 capsules/day = 1200 mg mycelium + 300 mg fruiting-body extract, for 8 weeks (n = 40). The control arm got the diet with no placebo, and the authors call the study a pilot for that reason. Depression, anxiety and sleep-disorder scores fell with the supplement; serum pro-BDNF rose at 8 weeks while BDNF did not change (it fell after the washout). The comparison was never against a placebo, as this record once said (abstract, PMID 31118969; full text, PMC6500611). 10.1155/2019/7861297
- Saitsu, Y., Nishide, A., Kikushima, K., Shimizu, K., Ohnuki, K. (2019). Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomedical Research, 40(4), 125-131. Three tests: MMSE, Benton visual retention, S-PA verbal paired-associate. ONLY the MMSE reached significance — the two memory tests did not. The story used to print the reverse. Full text: 34 randomized, 31 analysed (16 on H. erinaceus, 15 on placebo), all over 50; four supplements a day, each with 0.8 g powdered fruiting body, for 12 weeks (full text, Biomedical Research 40(4); abstract, PMID 31413233). 10.2220/biomedres.40.125
- Nagano, M., Shimizu, K., Kondo, R., Hayashi, C., Sato, D., Kitagawa, K., et al. (2010). Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomedical Research, 31(4), 231-237. 30 women randomised (26 analysed), mean age ~40 and classified healthy — not a menopausal cohort. Instruments were KMI, CES-D, PSQI and ICI; the story credited a CMI score, which was not used. 10.2220/biomedres.31.231